[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CU20130128A7 - Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi) - Google Patents

Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)

Info

Publication number
CU20130128A7
CU20130128A7 CU2013000128A CU20130128A CU20130128A7 CU 20130128 A7 CU20130128 A7 CU 20130128A7 CU 2013000128 A CU2013000128 A CU 2013000128A CU 20130128 A CU20130128 A CU 20130128A CU 20130128 A7 CU20130128 A7 CU 20130128A7
Authority
CU
Cuba
Prior art keywords
tfpi
monoclonal antibodies
inhibitor
antibodies against
antibodies
Prior art date
Application number
CU2013000128A
Other languages
English (en)
Inventor
Zhuozhi Wang
Jonh E Murphy
Tobias Marquardt
Dieter Moosmayer
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46932389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20130128(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of CU20130128A7 publication Critical patent/CU20130128A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan anticuerpos monoclonales aislados que se unen a epítopos específicos del inhibidor de la ruta del factor tisular humano (TFPI) y las moléculas de ácido nucleico aisladas que lo codifican. También se proporcionan composiciones farmacéuticas que comprenden los anticuerpos monoclonales anti- TFPI y procedimientos de tratamiento de deficiencias o defectos en la coagulación por la administración de los anticuerpos.
CU2013000128A 2011-04-01 2013-09-30 Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi) CU20130128A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161471101P 2011-04-01 2011-04-01
PCT/US2012/031538 WO2012135671A2 (en) 2011-04-01 2012-03-30 Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)

Publications (1)

Publication Number Publication Date
CU20130128A7 true CU20130128A7 (es) 2014-03-26

Family

ID=46932389

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2013000128A CU20130128A7 (es) 2011-04-01 2013-09-30 Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)

Country Status (37)

Country Link
US (5) US20140294832A1 (es)
EP (1) EP2694544B1 (es)
JP (4) JP6170903B2 (es)
KR (2) KR101995302B1 (es)
CN (2) CN103797030B (es)
AU (3) AU2012236296A1 (es)
BR (1) BR112013025376A2 (es)
CA (2) CA2831907C (es)
CL (1) CL2013002811A1 (es)
CO (1) CO6890074A2 (es)
CR (1) CR20130499A (es)
CU (1) CU20130128A7 (es)
CY (1) CY1121538T1 (es)
DK (1) DK2694544T3 (es)
DO (1) DOP2013000218A (es)
EA (2) EA201991704A3 (es)
EC (1) ECSP13012913A (es)
ES (1) ES2722824T3 (es)
GT (1) GT201300229A (es)
HK (1) HK1243426A1 (es)
HR (1) HRP20190467T1 (es)
HU (1) HUE042706T2 (es)
IL (4) IL228633B (es)
LT (1) LT2694544T (es)
MX (1) MX2013011218A (es)
MY (2) MY165499A (es)
PE (1) PE20141149A1 (es)
PH (4) PH12013502039A1 (es)
PL (1) PL2694544T3 (es)
PT (1) PT2694544T (es)
RS (1) RS58633B1 (es)
SG (2) SG193594A1 (es)
SI (1) SI2694544T1 (es)
TR (1) TR201905101T4 (es)
UA (1) UA113623C2 (es)
WO (1) WO2012135671A2 (es)
ZA (1) ZA201308169B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101792032B1 (ko) 2008-12-19 2017-11-02 백스터 인터내셔널 인코포레이티드 Ｔｆｐｉ 억제제 및 사용 방법
US8361469B2 (en) 2008-12-22 2013-01-29 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
DK2542257T3 (en) 2010-03-01 2017-10-16 Bayer Healthcare Llc OPTIMIZED MONOCLONAL ANTIBODIES AGAINST Tissue FACTOR ROAD INHIBITOR (TFPI)
KR101784030B1 (ko) 2010-03-19 2017-10-10 백스터 인터내셔널 인코포레이티드 Tfpi 저해제 및 사용 방법
CN103797030B (zh) * 2011-04-01 2017-05-31 拜尔健康护理有限责任公司 针对组织因子途径抑制物(tfpi)的单克隆抗体
KR102263685B1 (ko) * 2012-03-21 2021-06-11 다케다 야쿠힌 고교 가부시키가이샤 Tfpi 저해제 및 사용 방법
CN104185474B (zh) * 2012-03-30 2017-08-25 拜尔健康护理有限责任公司 蛋白酶调节的抗体
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
DK2970497T3 (da) 2013-03-15 2018-01-29 Bayer Healthcare Llc Anti-tfpi-antistofvarianter med differentiel binding over et ph-interval til forbedret farmakokinetik
WO2014140240A1 (en) 2013-03-15 2014-09-18 Novo Nordisk A/S Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor
WO2015007880A1 (en) * 2013-07-19 2015-01-22 Novo Nordisk A/S Antibodies recognizing the n-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
WO2016042093A1 (en) * 2014-09-17 2016-03-24 Novo Nordisk A/S Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161)
BR112017018328A2 (pt) 2015-02-25 2018-07-10 Mogam Institute For Biomedical Research anticorpo de ligação ao tfpi, método para produzir e composição compreendendo o mesmo
KR102068915B1 (ko) * 2015-08-19 2020-01-22 화이자 인코포레이티드 조직 인자 경로 억제제 항체 및 그의 용도
US20210263052A1 (en) * 2018-07-25 2021-08-26 Sony Corporation Blood coagulation system analysis device
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06153985A (ja) * 1992-11-16 1994-06-03 Teijin Ltd モノクローナル抗体
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
US8361469B2 (en) * 2008-12-22 2013-01-29 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
DK2542257T3 (en) * 2010-03-01 2017-10-16 Bayer Healthcare Llc OPTIMIZED MONOCLONAL ANTIBODIES AGAINST Tissue FACTOR ROAD INHIBITOR (TFPI)
CN103797030B (zh) * 2011-04-01 2017-05-31 拜尔健康护理有限责任公司 针对组织因子途径抑制物(tfpi)的单克隆抗体
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) * 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations

Also Published As

Publication number Publication date
HUE042706T2 (hu) 2019-07-29
AU2012236296A1 (en) 2013-10-24
KR20140019428A (ko) 2014-02-14
UA113623C2 (uk) 2017-02-27
RS58633B1 (sr) 2019-05-31
WO2012135671A3 (en) 2012-12-13
AU2017203105A1 (en) 2017-06-01
PE20141149A1 (es) 2014-08-28
US20220041752A1 (en) 2022-02-10
IL257145A (en) 2018-03-29
CO6890074A2 (es) 2014-03-10
SI2694544T1 (sl) 2019-06-28
TR201905101T4 (tr) 2019-05-21
HRP20190467T1 (hr) 2019-05-03
EA034214B1 (ru) 2020-01-17
PH12013502039B1 (en) 2013-12-16
DOP2013000218A (es) 2013-11-15
US20170107298A1 (en) 2017-04-20
SG10201602606UA (en) 2016-04-28
LT2694544T (lt) 2019-04-25
EA201991704A2 (ru) 2020-03-31
MY165499A (en) 2018-03-27
CA3068997A1 (en) 2012-10-04
ZA201308169B (en) 2016-03-30
AU2019201814A1 (en) 2019-04-04
PH12019500441A1 (en) 2020-10-12
PL2694544T3 (pl) 2019-07-31
PT2694544T (pt) 2019-04-02
CA2831907C (en) 2020-03-24
IL228633A0 (en) 2013-12-31
WO2012135671A2 (en) 2012-10-04
CY1121538T1 (el) 2020-05-29
PH12013502039A1 (en) 2013-12-16
ES2722824T3 (es) 2019-08-19
IL283829A (en) 2021-07-29
US20140294832A1 (en) 2014-10-02
EP2694544B1 (en) 2019-01-23
MY190951A (en) 2022-05-24
PH12019500440A1 (en) 2020-10-12
JP2018172411A (ja) 2018-11-08
HK1243426A1 (zh) 2018-07-13
CL2013002811A1 (es) 2014-02-28
DK2694544T3 (en) 2019-04-15
SG193594A1 (en) 2013-10-30
PH12019500439A1 (en) 2020-10-12
JP6363747B2 (ja) 2018-07-25
NZ615969A (en) 2016-01-29
ECSP13012913A (es) 2014-02-28
CN103797030A (zh) 2014-05-14
JP2017113019A (ja) 2017-06-29
CA2831907A1 (en) 2012-10-04
GT201300229A (es) 2014-11-13
US20180194857A1 (en) 2018-07-12
JP2021019619A (ja) 2021-02-18
EA201301107A1 (ru) 2014-11-28
IL274686B (en) 2021-09-30
US20190194353A1 (en) 2019-06-27
MX2013011218A (es) 2013-10-17
EP2694544A4 (en) 2015-03-25
CN103797030B (zh) 2017-05-31
BR112013025376A2 (pt) 2017-07-25
KR101995302B1 (ko) 2019-07-02
JP6170903B2 (ja) 2017-07-26
EA201991704A3 (ru) 2020-06-30
CR20130499A (es) 2013-10-24
KR20190079698A (ko) 2019-07-05
EP2694544A2 (en) 2014-02-12
CN107090046A (zh) 2017-08-25
JP2014511685A (ja) 2014-05-19
IL274686A (en) 2020-06-30
IL228633B (en) 2018-03-29

Similar Documents

Publication Publication Date Title
CU20130128A7 (es) Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)
ECSP12012134A (es) Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi)
ECSP11010810A (es) Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi)
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CY1121882T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
CY1117678T1 (el) Ενωσεις αναστολεων μεταλλοενζυμου
CY1120390T1 (el) Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων
CR20130624A (es) Proteínas de unión a antígeno
CU24498B1 (es) Anticuerpos de factor xi
EA201390772A1 (ru) Новые соли и полиморфные формы афатиниба
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201690159A1 (ru) Способы и композиции для лечения рака
CY1118254T1 (el) Αντισωματα toy βμρ-6
GT201300058A (es) Composiciones de anticuerpos anti-vegfr-3
BR112013027851A2 (pt) métodos para identificar um indivíduo caucasiano e para determinar uma suscetibilidade do indivíduo caucasiano de ter ou desenvolver a degeneração macular relacionada com a idade, e, kit
TH149802A (th) โปรตีนจับเกาะแอนติเจน
TR201200212A2 (tr) Risedronat içeren geliştirilmiş formülasyonlar.